ArticleScientific reports2026
Fibrocytes with different phenotypes are recruited in chronic obstructive pulmonary disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Previous studies showed that fibrocytes are increased in the circulation and in the airway walls of chronic obstructive pulmonary disease (COPD) patients. However, it is unclear whether fibrocytes express different phenotypes. The aim of the study was to further evaluate the recruitment and phenotypic characteristics of fibrocytes in patients and murine models with COPD. By using flow cytometry analysis, blood fibrocytes were enumerated and characterized in the fresh peripheral blood samples from 10 control subjects and 25 COPD patients. Tissue fibrocytes were detected by using multiplex staining and multispectral imaging analysis in COPD patients and murine models. Our analysis revealed no significant difference in the counts of total (CD45⁺Collagen I⁺) circulating fibrocytes, or those positive for the thymic stromal lymphopoietin receptor (TSLPR) or the chemokine CXCL12 receptor (CXCR4), between COPD patients and control subjects. In contrast, a significantly higher proportion of circulating fibrocytes expressed the IL-25 receptor (IL-17RA/IL-17RB) and the IL-33 receptor (sT2L) in COPD patients compared to controls. Furthermore, we demonstrated an increase in total fibrocytes, as well as IL-17RA/IL-17RB⁺, sT2L⁺, TSLPR⁺, CXCR4⁺, and smooth muscle actin α (α-SMA)⁺ fibrocytes, within the airway walls, alveolar walls, and alveolar spaces of both COPD patients and corresponding murine models. These results indicate that fibrocytes are elevated and exhibit an activated phenotype (α-SMA-positive) in the lung tissues of patients with COPD. These cells also express receptors for IL-25, IL-33, TSLP, and CXCL12. Taken together, these findings suggest that fibrocytes may participate in the development of peribronchial and pulmonary fibrosis in COPD, potentially mediated by epithelial-derived cytokines and chemokines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.